Allogene Therapeutics (ALLO) Accumulated Depreciation (2018 - 2019)

Allogene Therapeutics has reported Accumulated Depreciation for 2 years, with the latest figure at $1.6 million in Q1 2019.

• Quarterly Accumulated Depreciation changed N/A year-over-year to $1.6 million in Q1 2019, while the trailing twelve-month figure through Mar 2019 was $1.6 million (changed N/A YoY) and the FY2018 annual result came in at $1.0 million, changed N/A from the prior year.
• Accumulated Depreciation rose to $1.6 million in Q1 2019 per ALLO's latest filing, from $1.0 million in the prior quarter.
• Over five years, Accumulated Depreciation peaked at $1.6 million in Q1 2019 and troughed at $1.0 million in Q4 2018.